C-NETWORK
Hepatitis News Service
      28  September 2007
Hepatitis Council of Queensland Inc.
www.hepqld.asn.au

NEW WINTER ISSUE OF "THE HEP FACTOR" NEWSLETTER
SPECIAL EDITION: Alternative & Complementary Therapies
Topics include: Acupuncture, meditation, CH100, liver-cleansing diets and herbal
teas, rescue remedy, coffee, milk thistle, Reiki, essential Oils, Mic's Story
Part 2.
Download available here:
http://hepqld.asn.au/content/view/78/111/

HEPATITIS - NATIONAL AWARENESS WEEK: OCTOBER 1-7
Information and media releases:
http://hepqld.asn.au/content/view/77/98/

World Hepatitis Day
Humorous animation and flash game
http://www.hepatitisday.info/index.php

==========================
       LIVING WITH HEP C
==========================

What Baby Boomers, Seniors Need to Know About Hepatitis C
http://www.associatedcontent.com/article/384012/what_baby_boomers_seniors_need_t\
o_know.html

==========================
       TREATMENT & TESTING
==========================

Telaprevir for Hepatitis C Treatment
http://www.hcvadvocate.org/news/newsRev/2007/HJR-4.17.html#1

Long-term Complications after HCV Clearance
http://www.hcvadvocate.org/news/newsRev/2007/HJR-4.17.html#3

The University Of Nottingham In The British Midlands Announces Development Of
Possible Hepatitis C Vaccine
http://www.hcvadvocate.org/news/newsRev/2007/NewsRev-223.html#_The_University_Of

Genetic “Signature” Predicts Cirrhosis
http://www.hcvadvocate.org/news/newsRev/2007/HJR-4.17.html#4

NM Hepatitis C program wins international competition
http://www.hcvadvocate.org/news/newsRev/2007/NewsRev-223.html#_NM_Hepatitis_C

==========================
      DRUGS & ALCOHOL
==========================

Zero Tolerance on Drugs is Ill-informed - Anex Media Release
http://www.accessibility.com.au/news/zero-tolerance-on-drugs-is-illinformed

==========================
      HIV & HEP C CO-INFECTION
==========================

HIV rise blamed on belief in cure
http://news.bbc.co.uk/2/hi/health/7007859.stm
Young think HIV is curable - expert
http://www.guardian.co.uk/uklatest/story/0,,-6940666,00.html

League players spread HIV message in PNG
http://www.theage.com.au/news/World/League-players-spread-HIV-message-in-PNG/200\
7/09/22/1189881818949.html



Contributions and comments are welcomed, please email projects@...
Use the C-network to advertise projects, services or other important news!
To subscribe or unsubscribe to the C-network, please email
projects@... or visit http://www.hepqld.asn.au/cnetwork for more info.

Visit the Hepatitis Council of QLD at www.hepqld.asn.au
P.S. Don't forget to forward this email to a friend or colleague so that they
can join the C-network.


       Sick of deleting your inbox? Yahoo!7 Mail has free unlimited storage.
http://au.docs.yahoo.com/mail/unlimitedstorage.html


[Non-text portions of this message have been removed]

Hello,
I would like to invite everyone to take a look at this website so they can
research alternative
treatments for Hepatitis C.  The below link is a sample of one of the ebooks
from the site.
There is also tons of free information to research on the site.
Check it out at:
http://www.healthyhepper.com/sample2antioxidant.htm
Best Wishes!

Polymerase/Protease Inhibitors in Development

Drug Name Drug Category Pharmaceutical Company Clinical Phase
GSK625433 Polymerase Inhibitor GlaxcoSmithKline Phase I
Comments: Currently recruiting patients to study the initial safety
and tolerability in healthy adults as well as anti-viral activity.
(September 04, 2007)
TMC435350 Protease Inhibitor Medivir/Tibotec Phase I
Comments: A Phase I clinical study has been initiated. (February 9,
2007)
ITMN-191
(R-7227) Protease Inhibitor InterMune Phase I
Comments: Successful preclinical toxicology and pharmcokentic
studies have been completed. On December 19, 2006 InterMune
announced the commencement of a phase I trial will begin in January
2007 enrolling 74 healthy volunteers in France. On October 16, 2006
InterMune and Roche entered into an agreement to develop and
implement InterMune's protease inhibitor pipeline including ITNM
191. In early May 2007, InterMune reported that it had completed
dosing in a Phase 1a single ascending-dose (SAD) trial of ITMN-191
in healthy subjects. No serious adverse events were reported in the
SAD trial. Preliminary safety data from the SAD trial suggests that
ITMN-191 was well tolerated and safe at the doses intended for the
Phase 1b multiple-ascending dose (MAD) trial of ITMN-191. InterMune
announced on September 4, 2007 that HCV patient recruitment will
begin in September 2007 in Europe. (September 4, 2007)
R7128 Polymerase Inhibitor Pharmasset/Roche Phase I
Comments: Pharmasset in collaboration with Roche has begun the
multiple ascending dose portion of an on-going Phase I trial in 40
HCV genotype 1 patients to assess the safety, tolerability,
pharmacokinetics and antiviral activity of multiple doses of R7128
after once-daily or twice-daily dosing for 14 days.

On September 11, 2007 preliminary data on the study was released by
Pharmasset. It was found that there was a dose-dependent anitiviral
activity across all dosing arms with the 1,500 mg twice-daily arm
achieving a great than 99% decrease in HCV RNA (viral load). It was
also reported that R7128 was generally safe and well-tolerated with
no serious adverse events or any dose reductions due to adverse
events. Based on this data, Pharmasset/Roche plan to start a 28-day
study of R7128 in combination with Pegasys that is to begin late
September 2007. (September 18, 2007)
R1626 Polymerase Inhibitor Roche Phase II
Comments: AASLD 2006: 47 patients given oral doses (500 mg, 1500mg,
3000 mg, 4500) achieved viral load reductions of 1.2, 2.6, and 3.7
log 10 in the 100 mg, 300 mg and 4500 mg doses respectively. R1626
was generally well-tolerated with increasing adverse events at the
highest dose (4500 mg). No viral resistance was found. On October
13, 2005 Roche announced the start of a phase II study with R1626 in
combination with Pegasys plus Copegus and that R1626 has been
granted Fast Track status by the FDA. (November 8, 2006)
SCH 503034 (Boceprevir) Serine Protease Inhibitor Schering Phase II
Comments: In two studies presented at AASLD 2005, 61 genotype-1
patients in a 14-day course of treatment (5 treatment arms including
1 placebo arm), showed an HCV RNA reduction with the maximum HCV
reduction of more than 2 logs in the group receiving 400 mg of
SCH503034. SCH503034 was safe and well-tolerated with no serious
adverse events. In another study, SCH503034 in combination with Peg-
Intron resulted in a decrease of more than 2 logs overall with 4 out
of 10 subjects in the 400 mg arm achieving undetectable HCV RNA.
Phase II studies with the combination of SCH503034 and Peg-Intron
are underway. In April 2006, it was announced that patient
enrollment in this trial was completed. In January 2006 the FDA
granted Fast Track Designation. (April 17, 2007)
VX 950 (telaprevir) Protease Inhibitor Vertex Phase II
Comments Vertex has initiated two large multi-international studies
(Prove 2 and Prove 3) and has begun recruitment of Gentoype 1, 2, 3
treatment naïve and treatment experienced patients..
EASL:
In the three arms that included the combination of telaprevir,
Pegasys and ribavirin, it was found that 85% of patients were
undetectable at week 12 (less than 10 IU/ml) compared to43% in the
placebo plus Pegasys and ribavirin. The side effect profile was
comparable between treatment groups. The most common reason for
treatment discontinuation in the telaprevir arms was rash (7
patients). The early rapid response in the telaprevir arms indicate
that it might be possible to shorten treatment duration from 48 to
24 weeks for genotype 1 patients. In July 2007, Vertex reported on
some of the interim 12-week post treatment data from all patients
who finished the 24 weeks of the arm C ( PROVE I clinical trials).
Of the patients in this study who had undetectable HCV RNA (less
than 10 IU/mL) at the end of treatment, less than 10% had relapsed.
(July 28, 2007)
NM283 (Valopicitabine) Polymerase Inhibitor Idenix Pharmaceuticals
Phase II
Comments:.
Study 1--Non-responder study: Results reported from EASL found that
the trial failed to meet its goal, with no patients in this
difficult to treat group responding to the treatment. Study II –
Treatment naïve study: Phase II study results were released and it
was found that 72.2% of treatment naïve patients receiving the
valopicitabine, pegylated interferon plus ribavirin triple therapy
were HCV RNA negative after12 weeks compared to 61.5% in the group
receiving pegylated interferon plus ribavirin. Idenix announced that
they will be beginning a phase IIb dosing study of valopicitabine
(200 and 400 mg dose) in combination with pegylated interferon plus
ribavirin in about 300 genotype 1 treatment naïve patients towards
the end of 2007 and are planning a phase III study of triple therapy
for 2008.
In July 2007 the FDA placed the current clinical developed on hold
after valopicitabine failed a risk/benefit analysis performed by the
FDA. Idenix's CEO stated that he is not optimistic about the future
development of valopicitabine (July 28, 2007)



Anti Liver Cancer Drugs in Development

Drug Name Drug Category Pharmaceutical Company Clinical Phase
ZIO-101 Anti-Liver Cancer (Arsenic) ZIOPHARM Oncology Phase II
Comments; On May 10, 2007, ZIOPHARM announced the dosing of the
first patient in a phase II trial for the treatment of primary liver
cancer. This study is not specific to hepatitis C-related liver
cancer. (May 29, 2007)
GV1001 (Heptovax) Anti-Liver Cancer Pharmexa
Phase II

Comments: Initiation of phase II studies has begun in France, Spain
and Germany to treat liver cancer (HCC).The trail will enroll 41
patients with advanced liver cancer using GV1001 in combination with
GM-CSF (stimulates the production of neutrophils or white blood
cells). (December 12, 2006)
PI-88 Anti-liver cancer Progen Industries
Phase II

Comments: A treatment for primary liver cancer following surgical
resection of a liver tumour. Preliminary results from the Phase II
study of patients treated with 160 mg showed a substantial delay in
tumour recurrence compared to the patients who did not receive PI-
88. The final data is expected to be released by the second quarter
of 2007. (December 16, 2006)
Doxorubicin Transdrug Anti-liver cancer BioAlliance Pharma Phase
II/III
Comments: Drug-loaded nanoparticles that are used for the delivery
of drugs though intra-arterial, intravenous, or oral administration
to treat or slow down progression of primary liver cancer.
Initiation of phase II studies have been approved in France. The
phase II study will enroll 50 patients over three months. A larger
Phase III trial is also being planed that will expand the trial to
include up to 200 patients treated for 12 months. The Phase II and
III study will evaluate the disease progression to assess the
disease progression of liver cancer. Doxorubicin Transdrug has been
granted orphan drug status by the EMEA (Europe) and FDA (United
States). (December 16, 2006)
Nexavar (sorafenib) Anti-liver cancer Onyx Pharmaceuticals Phase III
Comments: It has been reported that in two clinical trials that that
Nexavar significantly improved overall survival rates of patients
with liver cancer and without any adverse events. Based on these
data, the company has halted the clinical trial so that all the
patients (including the placebo arm) in the trial could receive
Nexavar. According to a company press release, Onyx plans to seek
approval from the FDA and European health authorities as soon as
possible.

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc.
announced on June 27, 2007 that a Supplemental New Drug Application
(sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the
U.S. Food and Drug Administration (FDA) for the treatment of
patients with hepatocellular carcinoma (HCC), the most common form
of liver cancer. The company announced on August 20, 2007 that the
FDA has granted Nexavar priority review, which means that the review
process is expediated and the FDA will take action within sex months
of the date on which the FDA received the application. (September
04, 2007)



Drugs on Hold

Drug Name Drug Category Pharmaceutical Company Clinical Phase
XTL-6865 (formerly HepX-C) Monclonal Antibody XTL Biopharmaceuticals
Phase I
Comments: Results from a phase I trial evaluating XTL-6865 found
that it was safe in the doses given. XTL Bio announced that it is
seeking a collaborative partner for future development of the drug.
A future clinical trial will evaluate this compound in patients with
hepatitis C undergoing liver transplantation. XTL is considering
selling the rights to XTL-6865 or pursuing clinicial trials with a
partner. (June 8, 2007)
HCV-796 Polymerase Inhibitor ViroPharma/Wyeth Phase II/III
Comments: Phase II studies began recruiting and are expected to
complete enrollment in the second quarter of 2007. The Phase II
study will evaluate the safety, tolerability, antiviral activity,
and pharmacokinetics of HCV-796 in combination with pegylated
interferon plus ribavirin vs. pegylated interferon plus ribavirin in
HCV genotype 1 treatment naïve patients and in genotype 1 patients
who were non-responders to a previous course of HCV treatment.
Treatment duration will be 48 weeks with a 24 week follow-up period.
4 week data will be released in the 3rd quarter of 2007; 12-week
data will be released in the 4th quarter of 2007. EASL: Phase 1b
data (in combination with PEG_Intron) reported that there was an
additive antiviral effect across multiple genotypes in treatment
naïve patients. The HCV-796 twice daily dose used in combination
with Peg-Intron was generally well-tolerated – side effects were
consistent with the known side effects of interferons. There were no
dose limiting toxicities reported. On June 13, 2007, Viro Pharma
reported that the enrolment in 500 mg arm of the trial has been
completed. On June 27, 2007 ViroPharma announced that the FDA
granted fast track designation to HCV-796. Clinical Trial On-Hold:
On August 10, 2007 ViroPharma announced that it is discontinuing the
dosing of HCV-796 due to safety concerns. Viropharma will continue
to monitor the study participants for safety issues and the
effectiveness of the drug in patients treated. ViroPharma in
collaboration with Wyeth will determine the next steps in the
development of HCV-796 based on the review of safety and efficacy
data (August 17, 2007)
NM283 (Valopicitabine) Polymerase Inhibitor Idenix Pharmaceuticals
Phase III
Comments:. Study 1--Non-responder study: Results reported from EASL
found that the trial failed to meet its goal, with no patients in
this difficult to treat group responding to the treatment. Study II –
Treatment naïve study: Phase II study results were released and it
was found that 72.2% of treatment naïve patients receiving the
valopicitabine, pegylated interferon plus ribavirin triple therapy
were HCV RNA negative after12 weeks compared to 61.5% in the group
receiving pegylated interferon plus ribavirin. Idenix announced that
they will be beginning a phase IIb dosing study of valopicitabine
(200 and 400 mg dose) in combination with pegylated interferon plus
ribavirin in about 300 genotype 1 treatment naïve patients towards
the end of 2007 and are planning a phase III study of triple therapy
for 2008. In July 2007 the FDA placed the current clinical developed
on hold after valopicitabine failed a risk/benefit analysis
performed by the FDA. Idenix's CEO stated that he is not optimistic
about the future development of valopicitabine (July 28, 2007)

HCV Link to Cancer Found

by John C. Martin




A new study has uncovered the link between hepatitis C (HCV) and
cancer of the liver.1

Protein-Blocking Link Found
Scientists at the University of Texas Medical Branch at Galveston
have identified a key biochemical connection between the virus and
hepatocellular carcinoma.

The link is similar to that between the human papilloma virus (HPV)
and cancer of the cervix, according to Stanley Lemon, MD, the
study's lead investigator.

"What we've found is that one of the hepatitis C virus proteins
targets a cell protein that is critical for suppressing the
development of tumors, interfering with its ability to control
[cancer] cell proliferation," explained Lemon, who is director of
the Institute for Human Infections and Immunity and a professor of
Microbiology & Immunology and Internal Medicine. "By knocking out
this 'tumor suppressor' and promoting the proliferation of liver
cells, this viral protein is setting up the liver for cancer."

Latching on to a Beneficial Protein
The tumor-blocking protein is known as the retinoblastoma protein.
It normally lassos growing cancer cells, but when HCV is present,
scientists have found that the protein is greatly reduced in liver
cells. These cells contain a hepatitis C "replicon", a piece of HCV
genetic material that is able to reproduce itself in liver cells
used in lab experiments, and can also produce proteins made by the
hepatitis C virus.

What Lemon and his colleagues found was a viral protein that latches
on to the retinoblastoma protein, preventing it from halting
cancer. "The replicon experiments enabled us to identify a protein
known as NS5B that attaches to the retinoblastoma protein, a
critical tumor suppressor, and accelerates its breakdown," Lemon
explained.

"The way NS5B docks with the retinoblastoma protein is biochemically
almost identical to the way a protein made by human papilloma virus
does so to produce similar cancer-promoting results. That's
interesting," he says, "because the two viruses are so different;
HPV is a DNA virus, while hepatitis C is composed of RNA."

Paving the Way to Better Treatment?
Understanding exactly how the hepatitis C virus leads to the
development of hepatocellular carcinoma is critically important,
Lemon noted. Since there is no "silver bullet" treatment for
hepatitis C on the horizon, researchers must use the knowledge
they've gained in medical research to maximize the effectiveness of
various cancer-fighting therapies currently under development. This
will help doctors manage people with chronic illnesses like
hepatitis C in more effective ways with the aim of helping them
avoid cancer, he said.

According to the Centers for Disease Control and Prevention (CDC),
about 3.9 million Americans have been infected with HCV, of whom
approximately 2.7 million have chronic infection.2

It's also estimated that about 17,500 new cases of primary liver
cancer were diagnosed in 2005, and that some 15,400 people died from
the disease that year. While there are various forms of liver
cancer, the most common in adults is hepatocellular carcinoma. This
cancer has different growth patterns. Some begin as a single tumor
that grows outward, while others grow in many parts of the liver and
spread even further.3

Liver cancer is more common in developing countries in Africa and
East Asia than in the United States. In many of these countries, it
is the most common form of cancer.3

1. Munakata T, Nakamura M, Liang Y, Li K, Kemon SM. Down-regulation
of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B
RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 2005 ec 13;102
(50);18159-64. Epub 2005 Dec 6.
2. Centers for Disease Control and Prevention (CDC). Viral Hepatitis
C. Available at:
http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. Accessed
December 30, 2005.
3. American Cancer Society. What is Liver Cancer? Available at:
http://www.cancer.org/docroot/cri/content/
cri_2_2_1x_what_is_liver_cancer_25.asp. Accessed December 30, 2005.

John Martin is a long-time health journalist and an editor for
CuraScript. His credits include overseeing health news coverage for
the website of Fox Television's The Health Network, and articles for
the New York Post and other consumer and trade publications

Hepatitis Recurrence Rapid After Transplant, Warn Experts

by John C. Martin
  Article Date: 02-03-06



Experts are warning that hepatitis C (HCV) can return rather quickly
following a liver transplant. That's even after the transplant
itself helped significantly reduce viral levels. The findings are
reported in the February issue of the journal Liver Transplantation.1

The viral rebound, say the researchers from the Los Alamos National
Laboratory in New Mexico, can occur within a few days.

A Primary Transplant Cause
Hepatitis C is the primary reason for liver transplantation. Yet the
virus always recurs in the new liver, doctors have found.

In this study, chief investigators Kimberly Powers and Ruy Ribeiro
sought to use special mathematical calculations to determine the
odds, and quantity, of liver reinfection after a transplant.

For their research, the Los Alamos team in conjunction with the a
surgical team from Duke University Medical Center, followed six HCV-
infected patients who received livers from cadavers. The researchers
collected blood samples before, during and after transplantation to
evaluate blood levels of the virus in these patients. The
information was then plugged into the mathematical model used in the
study to calculate future varying viral loads following the
transplant procedures.

"In most patients, HCV RNA [genetic evidence of the virus' presence]
levels decreased rapidly during and after transplantation, and
subsequently began to increase, reaching above pre-transplant levels
in all but one patient, within a few days of the procedure," wrote
the medical research team.

Viral Rebound
They found that when the diseased liver was removed, viral load
dropped. But after the new liver was implanted, virus levels
continued to drop for up to 23 hours, then began to rise, doubling
every two days.

The investigators noted that in three patients, vial load plateaued
before rising, suggesting that some source other than the liver was
responsible for helping the virus maintain certain levels. However,
they were quick to add that these non-liver-based sources accounted
for only about four percent of total viral production. The rest
occurs directly in the liver.

The patterns of viral load decrease followed by increases are
consistent with previous study findings. The findings also suggest
that HCV can replicate (make copies of itself) rapidly in the post-
transplant patient taking immunosuppression therapy, typically given
to prevent liver rejection. This may mean that early antiviral
therapy may help delay or even prevent reinection, the study authors
wrote.

This study, the researchers pointed out, was limited by the small
number of patients, making it difficult to suggest that the findings
were similar to what would occur in the overall population of liver
transplant patients with hepatitis. The study also didn't take into
account the sources of viral replication, whether liver- or non-
liver-based.

"Nevertheless, the rapid HCV RNA decline … followed by the
postoperative increase observed in several patients … suggest that
the liver is the primary site of viral replication, with at most
small contributions from extrahepatic sites," Powers, Ribeiro, and
their colleagues concluded.

1. Powers KA, Riberio RM, Patel K et al. Kinetics of hepatitis C
virus reinfection after liver transplantation. Liver Transpl 2006
Jan 30;12(2):207-16 [Epub ahead of print].

John Martin is a long-time health journalist and an editor for
CuraScript. His credits include overseeing health news coverage for
the website of Fox Television's The Health Network, and articles for
the New York Post and other consumer and trade publications

by John C. Martin
  Article Date: 02-24-06



A derivative of a ubiquitous substance found in plants may be the
key to protecting people from liver cancer, suggests new research by
doctors at Johns Hopkins University.1

The compound is known by its chemical name: CDDO-Im. Scientists say
it protects lab animals from liver cancer and could be just as
powerful for humans. Studies involving people have yet to be
performed.

"The results show that the potency of this compound is more than 100
times as great" as other cancer-preventing therapies, explained
David Schwartz, MD, director of the National Institute of
Environmental Health Sciences at the NIH, which, along with the
National Cancer Institute, funded the study. "This protective
effect, combined with the compound's anti-inflammatory properties,
make it an exciting avenue for the prevention of other diseases, as
well."

CDDO-Im works by apparently removing toxic substances from liver
cells, thus increasing the cells' resistance to cancer-causing
poisons. Because it's effective at low doses, the Johns Hopkins
scientists stress that it could have potential for people,
particularly for those who have cancer with an inflammatory
component, such as those of the liver, colon, prostate and stomach.

The compound belongs to a class of cancer-fighting substances known
as triterpenoids (try-ter-puh-NOYDZ); it's manmade and derived from
oleanoic acid (oh-lee-uh-NOE-ik), a naturally-occurring substance
found in plants around the world.

It's also been suggested that other oleanolic-based compounds have
anti-cancer properties.2,3

To determine whether this particular triterpenoid fights off liver
cancer, researchers treated lab rates with varying doses of CDDO-Im.
Two days later, each animal was treated with aflatoxin, a naturally-
occurring toxin that causes liver cancer in animals.

They then evaluated the liver of each rat. Even at the lowest dose,
the compound led to an 85 percent reduction in pre-cancerous lesions
on the organs. These lesions aren't malignant, but have the
potential of eventually developing into cancer. "This compound has a
much greater effect at a far lower dose than any other compound
currently used for preventing aflatoxin-induced cancer in humans,"
said the study's lead investigator, Thomas Kensler, PhD, a cancer
biologist at the Johns Hopkins Bloomberg School of Public Health.

Kensler says CDDO-Im works by activating a protein that plays a key
role in protecting liver cells from the toxic effects of certain
environmental agents. The protein directs specific genes in the body
to "stimulate the cell's defense mechanisms," he explained. "The
protein also stimulates key enzymes that can detoxify agents like
aflatoxin and remove them from the cell."

Since the compound showed its powerful effectiveness on precancerous
lesions in the rodents used in this study, it will likely make an
excellent candidate as a drug to prevent liver cancer itself,
Kensler maintained.

"If this compound can produce such a potent and dramatic reduction
in the number of precancerous growths, it should have an equally
dramatic impact on the development of actual cancers," he said.

1. Yates MS, Kwak MK, Egner PA et al. Potent protection against
aflatoxin-induced tumorigenesis through induction of Nrf2-regulated
pathways by the Triterpenoid 1-[2-Cyano-3,12-Dioxooleana-1,9(11)-
Dien-28-Oyl] Imidazole. Cancer Res 2006 Feb 15;66(4):2488-94.
2. Konopleva M, Tsao T, Estrov Z et al. The synthetic triterpenoid 2-
cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-
dependent and –independent apoptosis in acute myelogenous leukemia.
Cancer Res 2004 Nov 1;64(21):7927-35.
3. Kim KB, Lotan R, Yue P et al. Identification of a novel synthetic
triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate that
potently induces caspase-mediated apoptosis in human lung cancer
cells. Mol Cancer Ther 2002;1:177-84.

John Martin is a long-time health journalist and an editor for
CuraScript. His credits include overseeing health news coverage for
the website of Fox Television's The Health Network, and articles for
the New York Post and other consumer and trade publications

C-NETWORK
Hepatitis News Service
      12 September 2007
Hepatitis Council of Queensland Inc., Australia
www.hepqld.asn.au


"Dame Anita Roddick dies aged 64"
http://news.bbc.co.uk/1/hi/uk/6988343.stm

Anita's article 'Hep C and Me' was published in the HCQ's Autumn issue of the
Hep Factor:
http://hepqld.asn.au/content/view/31/111/
Hepatitis Videos Online!
The Hepatitis Council of QLD is making a range of hepatitis c videos available
online through YouTube and GoogleVideo. These can be accessed via the HCQ
website at http://www.hepqld.asn.au. New videos will be added in the coming
weeks.

New Hep B Forum!
hep B forum is a new email distribution list that allows subscribers to keep up
to date about current events and happenings and to share ideas, exchange
opinions, and debate current issues relevant to local and national public health
responses to hepatitis B. hep B forum is hosted by Hepatitis Australia .
To subscribe to hep B forum  visit http://hepbforum.hepatitisaustralia.com and
follow the instructions on screen.

'Red Hot': Hep C Education Comic [NZ]
http://www.hicksville.co.nz/Red%20Hot%201.htm


==========================
      TRANSMISSION
==========================

Body Piercing Hervey Bay
http://www.health.qld.gov.au/healthieryou/body_piercing.asp

HCQ Body-piercing and Tattooing Info
http://hepqld.asn.au/content/view/73/1/

Hep C (Vaccine) hope hovers on the horizon
http://www.biopharma-reporter.com/news/ng.asp?n=79563-novartis-hepatitis-c-vacci\
ne

Immunity to hepatitis C virus infection: Update 2007
http://www.wjgnet.com/1007-9327/abstract_en.asp?f=4807&v=13

"A tiny cut turns into a close call"
http://www.latimes.com/features/health/la-he-practice3sep03,1,5323619.story?coll\
=la-headlines-health

Hepatitis E In Europe : Are Pigs Or Pork The Problem?
http://www.sciencedaily.com/releases/2007/09/070903205004.htm

World Journal of Gastroenterology
September issue full-texts online.
http://www.wjgnet.com/1007-9327/index.jsp

ACT Government tackles HIV, Hep C
http://abc.net.au/news/stories/2007/09/04/2024058.htm

Hepatitis in refugees who settle in Australia
http://www.racgp.org.au/afp/200709/18552


==========================
      TREATMENT
==========================

Does protracted antiviral therapy impact on HCV-related liver cirrhosis
progression?
http://www.wjgnet.com/1007-9327/abstract_en.asp?f=4903&v=13

Sorafenib (Nexavar) Demonstrates Promising Results for Hepatocellular Carcinoma
http://www.hivandhepatitis.com/hep_c/news/2007/090707_c.html


==========================
      HEP C / HIV CO-INFECTION
==========================

Fined over invisible condom HIV boast
http://www.news.com.au/dailytelegraph/story/0,22049,22371882-5001021,00.html
http://news.bbc.co.uk/2/hi/asia-pacific/6978421.stm

Investigating PNG's dark Aids secret
http://news.bbc.co.uk/2/hi/asia-pacific/6978421.stm

Nevirapine (Viramune) Hypersensitivity Reaction Increases the Risk of Death in
HIV/HCV Coinfected Individuals
http://www.hivandhepatitis.com/hiv_hcv_co_inf/2007/091107_a.html


==========================
      DRUGS & ALCOHOL
==========================

The heroin trial 10 years on: how politics killed hope [Alex Wodak]
http://www.ffdlr.org.au/commentary/Herointrial10yearson.htm

ANCD releases major report on compulsory drug treatment in Australia
http://www.ancd.org.au/media/media111.htm

A peer-education intervention to reduce injection risk behaviors for HIV and
hepatitis C virus infection in young injection drug users
http://feeds.feedburner.com/~r/wolterskluwer/aids/toccurrentrss/~3/147899126/abs\
tract.00002030-200709120-00012.htm

Case study: Accessible primary health care—A foundation to improve health
outcomes for people who inject drugs
http://www.ijdp.org/article/PIIS0955395906002337/fulltext

International Journal of Drug Policy
Volume 18, Issue 4, Pages 241-332 (August 2007). Full-text online.
http://www.ijdp.org/current


Contributions and comments are welcomed, please email projects@...
Use the C-network to advertise projects, services or other important news!
To subscribe or unsubscribe to the C-network, please email
projects@... or visit http://www.hepqld.asn.au/cnetwork for more info.

Visit the Hepatitis Council of QLD at www.hepqld.asn.au
P.S. Don't forget to forward this email to a friend or colleague so that they
can join the C-network.


      
________________________________________________________________________________\
____
Sick of deleting your inbox? Yahoo!7 Mail has free unlimited storage.
http://au.docs.yahoo.com/mail/unlimitedstorage.html


[Non-text portions of this message have been removed]

It's for everyone regardless of sexual orientation, race, and gender.
http://www.aboutme.com/users/ldssingle/STDsingles.htm

C-NETWORK
Hepatitis News Service
     20 August 2007
Hepatitis Council of Queensland Inc.
www.hepqld.asn.au

==========================
      GENERAL HEP C
==========================

Hep C Advocate Online Game-Show Quiz on Hepatitis C:
      http://www.hcvadvocate.org/quiz/Quiz_1/quiz_1.html


==========================
      LIVING WITH HEP C
==========================

Mistletoe and Hepatitis C
     
http://www.hepatitis-central.com/mt/archives/2007/08/a_plant_to_kiss.html?eml=he\
pcen36

Coffee Drinking Related To Reduced Risk Of Liver Cancer
     
http://www.hcvadvocate.org/news/newsRev/2007/NewsRev-216.html#_Coffee_Drinking_R\
elated

The Skinny on Fatty Liver Disease
     
http://www.hepatitis-central.com/mt/archives/2007/08/the_skinny_on_f.html?eml=he\
pcen36

'Walls of Paper' by moorlandt. Hepatitis C Awareness Song
      http://www.macjams.com/song/33744


==========================
      TREATMENT
==========================

Visible light pulses to zap HIV, Hepatitis C
     
http://www.hcvadvocate.org/news/newsRev/2007/NewsRev-216.html#_Visible_light_pul\
ses


==========================
       PRISONS
==========================

Prison Health: Inside Out
Paul Smith. Australian Doctor 27 July 2007.
     
http://www.australiandoctor.com.au/Common/ContentManagement/AusDoc/pdf/AD_037_04\
3b_JUL27_07.pdf

Guards veto needle plan Prison officers block syringe exchange in prison
     
http://canberra.yourguide.com.au/detail.asp?class=news&subclass=general&story_id\
=1032358&category=general


==========================
      INJECTING DRUG USE
==========================

Heroin crackdowns up risk of hep C infection
      http://www.australiandoctor.com.au/news/75/0c04da75.asp

Supervised injecting facilities: how much evidence is enough?
      http://members.westnet.com.au/paulgall/docs/MSICevidence.pdf


==========================
      HCV/HIV CO-INFECTION
==========================

HIV Audio Interview
      http://mpegmedia.abc.net.au/rn/podcast/current/audioonly/ats_20070726.mp3
"What's it like for a successful, single, heterosexual American female to be HIV
positive? We will introduce you to Regan Hofmann, editor-in-chief of Poz
magazine in New York, who guarded her secret for 10 years before going public in
2006 amid considerable media attention."

New Data Indicate Lower Number Of HIV/AIDS Cases In Papua New Guinea, Rapid
Spread Of Epidemic In Rural Areas
      http://www.medicalnewstoday.com/articles/79443.php

Novel HIV Treatment Approved
      http://www.medicalnewstoday.com/articles/79514.php

31% of HIV+ People in Australia Are Below Poverty Line
      http://www.samesame.com.au/news/local/1097/31_HIV_Below_Poverty_Line
     
http://www.smh.com.au/news/National/Many-HIV-sufferers-going-hungry-study/2007/0\
7/24/1185043068497.html

Papua Considers 'Chipping' People With HIV/AIDS
      http://www.thejakartapost.com/yesterdaydetail.asp?fileid=20070724.G04

Circumcision cuts HIV/AIDS risk by 60%
      http://abc.net.au/news/stories/2007/07/24/1986695.htm?section=justin

Pegylated Interferon Alfa-2a and Ribavirin Effective in HIV-Positive Patients
With Acute Hepatitis C: Presented at IAS
     
http://www.docguide.com/news/content.nsf/news/852571020057CCF685257322006B589E

IAS: Hepatitis C clusters reveal international transmission among HIV-positive
gay men
      http://www.aidsmap.com/en/news/C168511C-3344-4B0A-9AFF-302AD73C53FC.asp


==========================
      HEPATITIS B
==========================

Mummies provide clues to combat hepatitis B
      http://www.news-medical.net/?id=28098


==========================
       HEPATITIS COUNCIL OF QLD
==========================

The Torres Strait creole resource (produced by HCQ, QaHC, Men's & Women's Health
and the Torres Strait community) was the cover story for the Aboriginal and
Islander Health Worker Journal July/August 2007, Vol 31 – Number 4.
      http://www.aihwj.com.au/


Contributions and comments are welcomed, please email projects@...
Use the C-network to advertise projects, services or other important news!
To subscribe or unsubscribe to the C-network, please email
projects@... or visit http://www.hepqld.asn.au/cnetwork for more info.

Visit the Hepatitis Council of QLD at www.hepqld.asn.au
P.S. Don't forget to forward this email to a friend or colleague so that they
can join the C-network.


      
________________________________________________________________________________\
____
Sick of deleting your inbox? Yahoo!7 Mail has free unlimited storage.
http://au.docs.yahoo.com/mail/unlimitedstorage.html


[Non-text portions of this message have been removed]

C-NETWORK
Hepatitis News Service
   24 July 2007
Hepatitis Council of Queensland Inc. Australia
www.hepqld.asn.au

==========================
      GENERAL HEP C
==========================

"Llama Lashes and Grumpy Old Gits"
Living with hepatitis C play/documentary by BBC’s Radio 4
      http://www.theboltons.plus.com/Llama_Lashes.mp3

Protecting Yourself From Hepatitis C
      http://www.abcnews.go.com/Health/Germs/story?id=3374166&page=1

Impact of Hepatitis C on Health Related Quality of Life
      http://www3.interscience.wiley.com/cgi-bin/fulltext/110432951/PDFSTART

New music CD gets South Asian audiences 'tuned in' to hepatitis C
      http://www.hepc.nhs.uk/news/newsarchive/archive2006/Page-15519.html

Hepatitis C Literature Review, 3 - 10 July 2007
      http://hepccentre.org.uk/literaturetemplate.htm


==========================
      LIVING WITH HEP C
==========================

HCV and the Body's Most Important Antioxidant
     
http://www.hepatitis-central.com/mt/archives/2007/07/hcv_and_the_bod.html?eml=he\
pcen34

The Emotional Impact of Leaving Work on Disability
     
http://www.hcvadvocate.org/hepatitis/hepC/Emotional%20Impact%20of%20Leaving%20Wo\
rk.html


==========================
      TREATMENT
==========================

Factors That Affect Success of Interferon-based Treatment for Hepatitis C
      http://www.hivandhepatitis.com/hep_c/news/2007/071707_a.html

Shortened Hepatitis C Treatment Increases Relapse Rate
     
http://www.hepatitis-central.com/mt/archives/2007/07/shortened_hepat.html?eml=he\
pcen34

Researchers Isolate Genes That Battle Hepatitis C Virus
     
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525731B00758FE1

Gender Disparity in Liver Cancer May Be Due to Estrogen-mediated Inhibition of
Interleukin 6
      http://www.hivandhepatitis.com/hep_c/news/2007/072407_a.html


==========================
      TESTING
==========================

Siemens Medical Solutions Diagnostics Announces Enhanced Liver Fibrosis Test for
Europe
      http://biz.yahoo.com/bw/070718/20070718005490.html?.v=1


==========================
      INJECTING DRUG USE
==========================

Australian NSP Survey National Data Report 2002 - 2006
      http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/page/Australian%20NSP%20Survey


Illicit Drug use in Australia: Epidemiology, use patterns and associated harm
     
http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Cont\
ent/17B917608C1969ABCA257317001A72D4/$File/mono-63.pdf


==========================
      HCV/HIV CO-INFECTION
==========================

Response to Treatment of Acute Hepatitis C in HIV-HCV Coinfected Patients
      http://www.hivandhepatitis.com/2007icr/ias/docs/072407_c.html

Protecting HIV Patients From Hepatitis B Virus
      http://www.medicalnewstoday.com/articles/77246.php

Preservation of HCV-specific CD4 T-cell Responses in the Livers of HIV-HCV
Coinfected Individuals
      http://www.hivandhepatitis.com/hiv_hcv_co_inf/2007/072007_b.html


==========================
      HEPATITIS B
==========================

Researchers measure effect of hepatitis B on patients' quality of life
      http://www.news-medical.net/?id=27444

Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of
Standard Treatment Criteria and Endpoints
      http://www.hivandhepatitis.com/hep_b/news/2007/072007_a.html


==========================
      NATIONAL/GLOBAL EVENTS
==========================

Brisbane 2008
Viral Hepatitis 6th Australasian Conference
Monday 20 October - Wednesday 22 October
      http://www.hepatitis.org.au

International HBV Meeting 2007
September 16-20, 2007, Rome, Italy
      http://www.hbvmeeting.org/


Contributions and comments are welcomed, please email projects@...
Use the C-network to advertise projects, services or other important news!
To subscribe or unsubscribe to the C-network, please email
projects@... or visit http://www.hepqld.asn.au/cnetwork for more info.

Visit the Hepatitis Council of QLD at www.hepqld.asn.au
P.S. Don't forget to forward this email to a friend or colleague so that they
can join the C-network.


       Yahoo!7 Mail has just got even bigger and better with unlimited storage on
all webmail accounts.
http://au.docs.yahoo.com/mail/unlimitedstorage.html




[Non-text portions of this message have been removed]

You just need to create anonymous personal ad. Then you can search
other people's ads from all over the world. Email other women who have
std. Chat online. Meet in real world. Date and love ideal woman.

If you are interested, please click the following link to create ad:
http://STDDating.zu5.net

You just need to create anonymous personal ad. Then you can search
other people's ads from all over the world. Email other women who have
std. Chat online. Meet in real world. Date and love ideal woman.

If you are interested, please click the following link to create ad:
http://STDDating.zu5.net

To whom it may concern;

My name is Jason Cutler, and I'm writing you from MedQuest
Facilities and Recruiting, Inc, here in Chicago.  I'm writing you
today regarding a market research study we're conducting with
patients who've been diagnosed with Hepatitis C. The study is done
on-line, takes about 45 minutes, and we do compensate the
participants with a $50 honorarium.

Rather than rudely poster a flyer announcing this study on message
boards, I'm forwarding it to you, in case you think there are any
members of your group who might be interested. If you have any
additional questions or concerns regarding either the study or
MedQuest, please don't hesitate to write back.

Thank you, and have a wonderful day!


HEPATITIS C PATIENTS NEEDED
for Paid On-line Survey

MedQuest, a medical market research company, is looking for
individuals who have been diagnosed with chronic Hepatitis C to
participate in an anonymous on-line market research survey.

Participants will receive $50 if they qualify for and complete a 45-
minute survey.

Upon survey completion, qualified respondents will be entered into a
lottery of 500 people with a chance to win an additional $500.

Please log onto http://www.hepcsurvey.com/ to complete the survey

To learn more about MedQuest, you can visit us at:
www.medquest-chicago.com


Jason M. Cutler
Medquest
850 W. Jackson Blvd.
suite 430
Chicago, Il 60647
(877)666-8863

This is an interview with a Tibetan Physician who works in India under
the patronage of His Holiness the Dalai Lama. The results of Tibetan
Herbal Medicine on all Hepatitis virus -- including B + C -- has been
extremely under-publicized.

See blog: http://dalailamahepatitismedicine.wordpress.com

See article:
http://dalailamahepatitismedicine.wordpress.com/conversation-with-
tibetan-physician/

A Real Hepatitis Remedy by Tibetan Physician,
Dr. Yeshi (C.M.O)

Do you have any Western Training?

No, we don't have Western Training. But we have also had to study
many books on Western medicine. Because these are modern times, we
now have daily practice and experience and know many Western
doctors. We read Pathological reports, X-ray reports and Blood reports.

Why did you become a doctor?

There is no question it is because I wanted to help people but it is also
because Tibetan medicine is a unique medicine and it is our history and
culture. The second reason is that in Western or Traditional medicine it
is the best profession. Even after we are retire we can still help people
as we are then even more experienced ?even more proficient.

Are all Tibetan Physicians connected to His Holiness the Dalai Lama?

All Tibetan physicians are under the Tibetan Government and His
Holiness the Dalai Lama patronage. There are some who are the
personal physicians to His Holiness the Dalai Lama himself but these are
only a few. They are more experienced and more senior. Only a few
are selected for that.

What is the success rate of Tibetan Medicine in treating all Hepatitis
infection? You had previously told me about up to 75% -- is that correct?

Yes, yes.

How does Tibetan Medicine work?

If a patient takes Tibetan Medicine, it prevents more damage to the
liver. I am talking about Hepatitis B & C. We protect the liver by
deflecting disease and we begin to actually heal the damage. The many
compounds in the preparation of Hepatitis medicine also fight the virus.
After using Tibetan Medicine for 6 months, the liver begins to function
more normally even if the virus remains.
But in the cases of Hepatitis B or C -- if we are talking about seeing the
virus go from positive to negative this happens only rarely.

Are you saying that the virus may not be eradicated completely?

After using Tibetan Medicine and adhering to the diet, the liver's normal
functioning progresses and the virus count is reduced but the virus may
still remain though it no longer does damage.

Can you say how much the virus count is reduced?

There are no guarantees. This depends on a persons general health
conditions and if he has other diseases. But if all the conditions are good
and if he follows his diet and takes his medicine regularly, the virus
count will go down about 50-65%. This is very possible using Tibetan
Medicine.

If someone has an adverse reaction to the Tibetan Herbal Medicine,
what do you suggest they do?

If you mean side effects? I would say that this was a very rare case.
Very, very rare. And I can say it happens only seldom. Using Tibetan
Herbal Medicine for Hepatitis prevents many other liver diseases and
does not let the liver worsen into cirrhosis and liver cancer. These are
some of the reasons why Tibetan Medicine is such a good tradition and
is so effective.

What if he is taking Western medicine -- for blood pressure for
example -- will it interfere?

No, no. It will not interfere. In such conditions if a patient must use
Western medicine, he can continue using it along with his Tibetan
medicine but he must keep a 1 to 2 hour difference between the two.
Then there will be no problem.

In Tibetan Traditional Medicine, the Pulse and Urine are used to make a
diagnosis. If a person is unable to visit a Tibetan doctor, can you
diagnose accurately based on the patient's Liver Function Test (LFT),
recent Blood work, along with the questions you posed?

Yes. This is easy to handle.

How long does the treatment take?

We explain to the patient that the treatment can take 6 months to 2
years of taking the medicine.  We don't like to give a specific duration
because if a patient has Hepatitis B or C and after taking the Tibetan
Medicine for approximately 1 year he has greatly improved, the doctor
may say he can stop. But if the patient has had a great deal of progress,
he may still want to further the treatment for another year. Mostly
people stop because of having monetary problems.

So a patient can expect a treatment to last 6 months to 2 years -- if the
medicine is working, right?  But what if someone has been taking the
medicine for only one month -- will they begin to see any improvement?

Yes. After using the Tibetan Medicine one month -- there will be definite
improvement. If he has symptoms like loss of appetite, fatigue, jaundice
and fever, he will see improvement in all these areas.
The problem is with Hepatitis B or C he may not have any outer
symptoms. He may look normal and healthy. If a patient does not have
any symptoms he will not feel different after taking Tibetan Medicine for
one month. Though the tests too will show improvement.

Do you see Traditional and Western medicine working together in the
future?

Traditional Tibetan Herbal Medicine and Western pharmaceuticals are
two different systems and work in two different ways.

If a person in the West begins treatment with you, can he call you here
in the office for advice?

Yes, of course.

Updates in Cancer research work   New Weapon Against Cancer: HIV Protein
Enlisted To Help Kill Cancer Cells  Cancer cells are sick, but they keep growing
because they don't react to internal signals urging them to die
   Genetic Fingerprints Identify Brain Tumors' Origins  Metastasis Cancer:
Questions and Answers  Anti-cancer chicken eggs produced
   For detail on article see the link
   http://www.studyandjobs.com/Cancer.html
   Thanx


---------------------------------
Ahhh...imagining that irresistible "new car" smell?
  Check outnew cars at Yahoo! Autos.

[Non-text portions of this message have been removed]

I am Lisa, a sentimental but optimistic girl. I feel so lone and
helpless when I was told that I had affected with HIV.
However, someday I read an article about a online dating site for people
living with STD at CNN. At that time, I had no idea about that whether I
should have a try on it. But now I have to say that PozCommunity really
brings me a great deal of pleasure. It is the best wonderful site I have
not ever seen.
If you are interested in it, you can go there:
http://www.aboutme.com/users/ldsheaven/happylife.htm
<http://www.aboutme.com/users/ldsheaven/happylife.htm>

If you are not interested in it, you can go there:
http://groups.yahoo.com/group/freetopozcommunity/
<http://groups.yahoo.com/group/freetopozcommunity/>
http://groups.yahoo.com/group/STDeternallovewithyou
<http://groups.yahoo.com/group/STDeternallovewithyou>



[Non-text portions of this message have been removed]

HIV Protein Enlisted To Help Kill Cancer Cells
   Cancer cells are sick, but they keep growing because ... detail at
http://www.studyandjobs.com/HIVProtein_Cancer.html
or
http://www.studyandjobs.com/Cancer.html
   Thanx


---------------------------------
Never miss an email again!
Yahoo! Toolbar alerts you the instant new Mail arrives. Check it out.

[Non-text portions of this message have been removed]

As there are few options for chat for those with Hepatitis C we have
created an easy, free, way to access chat at
http://www.starchat.net/msntv/ just put in your nickname and for chat
room name put #hepchat no password is necessary, then click log in.  if
you are using mIRC for chat you can access the room by selecting
starchat as your server and then join #hepchat.  Hope to see you there
sometime.

Ourhepchat staff

--- In lonestarheppers@yahoogroups.com, jimmmr1 <no_reply@...> wrote:
>
> Hey Black Diamond! Long time.
>
> Jimmmr here in Lubbock. Alot has gone on since we last chatted. I
have
> been on Peg w/o Riba for the last 37 months on a maintainence basis.
> Non-detect and labs all normal for quite a while now. I'm blessed.
> Transplant I got in 2000 is doing great. I think I am their poster
boy
> over at Methodist Liver Center in Houston. Lost my wife in the
process.
> Divorce final over a year ago. Her and my two kids 28 & 21 are still
> there in Bastrop in the house I built them. Kids are doing well. We
get
> to see each other occasionally when I head down to Houston for labs
and
> MRI's and such. Guess they are right when they say something like
this
> will either break a relationship or make it stronger. you can guess
> which way it worked for me.
>
> Was tough, was married to my high school sweetheart for 30 years.
Guess
> she decided she wanted something or someone different. Well her
loss.
> Things are great now. Stayed with my brother in The woodlands after
we
> separated and went through a long 2 yrs of failed reconciliation
efforts
> and divorce crap. Since then have found a wonderful woman named
Mary who
> treats me like solid gold and that is why I am in Lubbock. She is a
> manager at JC Pennys. We met a year and a half ago, on a SW Airline
> flight between Dallas and Las Cruces NM and we have been a pair
every
> since. What a woman, never even flinched about the HCV and insomnia
> thang. Wow what do you think the chances of that is? We can't
really get
> married since I don't have insurance and with a combined income
would
> not qualify for the assistance I get from Methodist in Houston and
the
> Peg and Prograf manufacturers. If you recall my insurance company
> dropped me right after the txp. You can keep up with me at my blog:
> www.jimmmmr.blogspot.com <http://www.jimmmmr.blogspot.com> .
>
> My biz has been good doing graphics and web work for oil companies.
Work
> at home which I have done since my txp. www.focusarts.com
> <http://www.focusarts.com> .
>
> Ride a Yamaha VStar 1100 Classic cruiser with a Christian Motorcycle
> Ministry that is nationwide. Having a blast doing that. I do the
website
> for them also. www.fellowshipriderslubbock.org
> <http://www.fellowshipriderslubbock.org> . Also did a website for a
> chapter in Florida www.fellowshipridersfloridaeverglades.com
> <http://www.fellowshipridersfloridaeverglades.com>  . Compete in an
APA
> nine ball billiard league and just having a great time thanking God
for
> an awesome "do-over".  There can be life after HCV and even a txp.
I am
> blessed.
>
> Hang in there BD, never give up. Life goes on even on treatment.
God has
> always showed me a "workaround" when faced with all the challenges
that
> the dragon presents.
>
> When it's you and God even the facts don't count and all things are
> posible.
> You take care and God Bless,
> Jimmmr in Lubbock
>
>
>
>
> --- In lonestarheppers@yahoogroups.com, blackdiamond_36 <no_reply@>
> wrote:
> >
> > Hello all
> >
> > I just wanted to let you know that the Peg and riba is working
again
> > for me today. I just got back my viral load which went from
250,000
> > to 19,000 as of the report I saw today.  The tx seems to hit me
hard
> > in the 1st 24 hours after taking it and just drains my body. I
have
> > also had some depression and had to change back to Celexa to deal
> > with it. My energy level also gets drained by the end of the day.
> > One good thing is that since I started tx I have added to my
morning
> > routine walking about 2 miles per day which I feel is doing good
for
> > me and helping with some of the sides. Tonight will be shot #7 out
> > of too many to count. But if it works it will be worth it in the
> > long run. I will also be working on a local support group for hear
> > in Austin for Hcv patients which will be linking this site with
> > these patients so we can all give support to each other. In the
next
> > few weeks I will also be updating links and adding some new sites
to
> > Lone Star Heppers. I encourage you all to post only information
and
> > links for HCV patients in the next month.
> >
> > Thanks
> > BD
> >
>
>
>
> [Non-text portions of this message have been removed]
>

Patients with lung cancer that has spread to mediastinal lymph nodes -- located
between the chest, breastbone and spine -- who receive radiation after surgery
and chemotherapy live twice as long as patients who do not receive radiation
after surgery, according to a study presented at the plenary session November 6,
2006, at the American Society for Therapeutic Radiology and Oncology's 48th
Annual Meeting in Philadelphia.

   http://www.studyandjobs.com/radiation_lung_cancer.html

   or
   http://www.studyandjobs.com/Cancer.html

   Regards


---------------------------------
Sponsored Link

$200,000 mortgage for $660/mo - 30/15 yr fixed, reduce debt, home equity - 
Click now for info

[Non-text portions of this message have been removed]

Hi I dont post much Not much at all Im angel in Texas So heres a email to say Hi
and hope to get to know you and everybody here



Beauty is in the scent of a flower,the wisp in the wind,the song of the
birds,the smile of a friend.So always take time to see ,that the most beautiful
things are free.

---------------------------------
Everyone is raving about the all-new Yahoo! Mail beta.

[Non-text portions of this message have been removed]

THURSDAY, Sept. 28 (HealthDay News) -- Women may have an edge on men
when it comes to surviving liver transplant, a new British study
finds.


The study of over 2,700 patients who received a liver transplant
between 1985 and 2003 found that female patients live an average of
4.5 years longer than their male counterparts.


According to researchers at Queen Elizabeth Hospital, Birmingham,
average survival time for the patients in the study was 22 years,
compared with 29 years for a comparison group of healthy people of
similar age.


Average life expectancy for female liver transplant patients was 26
years, compared with 18 for males. The average life expectancy for
the general population was 31 years for women and 27 years for men.


Liver transplant patients ages 17 to 34 had an average life
expectancy of 28 years. While this was the highest among the
transplant patients, it fell far short of the average life
expectancy of 51 years for people ages 17 to 34 in the general
population.


Overall, patients who required a liver transplant due to primary
liver disease had significantly longer survival times than those who
had transplants due to hepatitis C, cirrhosis, or cancer.

mary miller <mary1187@...> wrote:  Date: Fri, 18 Aug 2006 08:56:02
-0700 (PDT)
From: mary miller <mary1187@...>
Subject: ScienceDaily: Statins Stop Hepatitis C Virus From Replicating
To: mary1187@...

Please see the following page ... Title: ScienceDaily: Statins Stop Hepatitis C
Virus From Replicating Link:
http://www.sciencedaily.com/releases/2006/07/060709125024.htm


[Non-text portions of this message have been removed]

--- In lonestarheppers@yahoogroups.com, "mary" <mary1187@...> wrote:
>
> --- In lonestarheppers@yahoogroups.com, blackdiamond_36
> <no_reply@>
> wrote:
> >
> > Well this is to let all of my Hepper friends know that doc and I
> had
> a
> > visit. I am showing signs of stage 2 which is not good. Because
of
> > this I will be going back on Peg with Riba for 4 years to see if
I
> can
> > slay the dragon. Because of this I will be doing more post of
> > information for Hcv patients her on Lone Star Heppers. Would
like
> to
> > know if any of you would like to get back to having chats again
in
> > hear 1 night out of the week. Looks forward to hearing from you
> all
> as
> > I draw my sword.
> >
> > Thanks
> > Blackdiamond
> >
> Blackdiamond good blessings to you. I hope you make it, keep the
> faith.
> Why four years,I thought 48 weeks was max.I am new to this site
and
>  just looking for friends to chat with. Mary

Mary

This is what I was able to find out about why so long for tx. I did
ask questions and he had just got back from a Hcv conference dealing
with TX. What they are finding is that if a patient goes on tx for
for 6 months and is able to clear the virus. Then they move start
second round for 48 months which keep the virus from comming back.
Then after the 48 months it increases the the chance for genotypes
1a and 1b of them staying in remission to 46 %. Also they have found
that it starts to heal the damaged liver. Hopes that this is not to
technical.

Thanks
BD

mary miller <mary1187@...> wrote:   Date: Fri, 25 Aug 2006 17:47:43
-0700 (PDT)
From: mary miller <mary1187@...>
Subject: Fwd: A Medscape article that might interest you.
To: lonestarheppers@yahoogroups.com



Note: forwarded message attached.From: mary1187@...
To: mary1187@...
Subject: A Medscape article that might interest you.
Date: Fri, 25 Aug 2006 20:41:42 -0400 (EDT)

I thought you might be interested in this.
http://www.medscape.com/viewarticle/532936
To access the article, click on this Web address, or cut and paste it into a
browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE
* Free Online CME
* 25+ medical specialty sites
* 100+ online medical journals
* Conference Coverage
* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the
mobile professional.





[Non-text portions of this message have been removed]

--- In lonestarheppers@yahoogroups.com, "Richard" <rpmdata2001@...>
wrote:
>
> I have had HepC since 1994 and have gone through two treatments.
> still carrying a load and will try new regimen this fall.  This is
> new because I have never really talked or shared with others.  Hi.
> There, that's a beginning.
>
> Richard
>
hey ,how did your new tx. go i hope things are going well mary

--- In lonestarheppers@yahoogroups.com, blackdiamond_36
<no_reply@...>
wrote:
>
> Well this is to let all of my Hepper friends know that doc and I
had
a
> visit. I am showing signs of stage 2 which is not good. Because of
> this I will be going back on Peg with Riba for 4 years to see if I
can
> slay the dragon. Because of this I will be doing more post of
> information for Hcv patients her on Lone Star Heppers. Would like
to
> know if any of you would like to get back to having chats again in
> hear 1 night out of the week. Looks forward to hearing from you
all
as
> I draw my sword.
>
> Thanks
> Blackdiamond
>
Blackdiamond good blessings to you. I hope you make it, keep the
faith.
Why four years,I thought 48 weeks was max.I am new to this site and
  just looking for friends to chat with. Mary

I just went to my Dr. for a second round of tx. She said it was to
soon. my first round was terrible I had to go on half a dose ,my white
blood cells went hay wire I had to get bossters to help my white blood
cells get back up to par. I had trouble getting blood drawn ,. I  had
a ton of problems. I went for a clinical trial and could not begin
because my veins were depleted. Any sggestions on how to get blood
when the veins are no longer there. thats my story. would love to
talk. By the way there is a medicin coming out hopefully soon by the
name of vx950 have any body heard of it,

Hey Black Diamond! Long time.

Jimmmr here in Lubbock. Alot has gone on since we last chatted. I have
been on Peg w/o Riba for the last 37 months on a maintainence basis.
Non-detect and labs all normal for quite a while now. I'm blessed.
Transplant I got in 2000 is doing great. I think I am their poster boy
over at Methodist Liver Center in Houston. Lost my wife in the process.
Divorce final over a year ago. Her and my two kids 28 & 21 are still
there in Bastrop in the house I built them. Kids are doing well. We get
to see each other occasionally when I head down to Houston for labs and
MRI's and such. Guess they are right when they say something like this
will either break a relationship or make it stronger. you can guess
which way it worked for me.

Was tough, was married to my high school sweetheart for 30 years. Guess
she decided she wanted something or someone different. Well her loss.
Things are great now. Stayed with my brother in The woodlands after we
separated and went through a long 2 yrs of failed reconciliation efforts
and divorce crap. Since then have found a wonderful woman named Mary who
treats me like solid gold and that is why I am in Lubbock. She is a
manager at JC Pennys. We met a year and a half ago, on a SW Airline
flight between Dallas and Las Cruces NM and we have been a pair every
since. What a woman, never even flinched about the HCV and insomnia
thang. Wow what do you think the chances of that is? We can't really get
married since I don't have insurance and with a combined income would
not qualify for the assistance I get from Methodist in Houston and the
Peg and Prograf manufacturers. If you recall my insurance company
dropped me right after the txp. You can keep up with me at my blog:
www.jimmmmr.blogspot.com <http://www.jimmmmr.blogspot.com> .

My biz has been good doing graphics and web work for oil companies. Work
at home which I have done since my txp. www.focusarts.com
<http://www.focusarts.com> .

Ride a Yamaha VStar 1100 Classic cruiser with a Christian Motorcycle
Ministry that is nationwide. Having a blast doing that. I do the website
for them also. www.fellowshipriderslubbock.org
<http://www.fellowshipriderslubbock.org> . Also did a website for a
chapter in Florida www.fellowshipridersfloridaeverglades.com
<http://www.fellowshipridersfloridaeverglades.com>  . Compete in an APA
nine ball billiard league and just having a great time thanking God for
an awesome "do-over".  There can be life after HCV and even a txp. I am
blessed.

Hang in there BD, never give up. Life goes on even on treatment. God has
always showed me a "workaround" when faced with all the challenges that
the dragon presents.

When it's you and God even the facts don't count and all things are
posible.
You take care and God Bless,
Jimmmr in Lubbock




--- In lonestarheppers@yahoogroups.com, blackdiamond_36 <no_reply@...>
wrote:
>
> Hello all
>
> I just wanted to let you know that the Peg and riba is working again
> for me today. I just got back my viral load which went from 250,000
> to 19,000 as of the report I saw today.  The tx seems to hit me hard
> in the 1st 24 hours after taking it and just drains my body. I have
> also had some depression and had to change back to Celexa to deal
> with it. My energy level also gets drained by the end of the day.
> One good thing is that since I started tx I have added to my morning
> routine walking about 2 miles per day which I feel is doing good for
> me and helping with some of the sides. Tonight will be shot #7 out
> of too many to count. But if it works it will be worth it in the
> long run. I will also be working on a local support group for hear
> in Austin for Hcv patients which will be linking this site with
> these patients so we can all give support to each other. In the next
> few weeks I will also be updating links and adding some new sites to
> Lone Star Heppers. I encourage you all to post only information and
> links for HCV patients in the next month.
>
> Thanks
> BD
>



[Non-text portions of this message have been removed]

Hello all

I just wanted to let you know that the Peg and riba is working again
for me today. I just got back my viral load which went from 250,000
to 19,000 as of the report I saw today.  The tx seems to hit me hard
in the 1st 24 hours after taking it and just drains my body. I have
also had some depression and had to change back to Celexa to deal
with it. My energy level also gets drained by the end of the day.
One good thing is that since I started tx I have added to my morning
routine walking about 2 miles per day which I feel is doing good for
me and helping with some of the sides. Tonight will be shot #7 out
of too many to count. But if it works it will be worth it in the
long run. I will also be working on a local support group for hear
in Austin for Hcv patients which will be linking this site with
these patients so we can all give support to each other. In the next
few weeks I will also be updating links and adding some new sites to
Lone Star Heppers. I encourage you all to post only information and
links for HCV patients in the next month.

Thanks
BD